- Home
- JBLU vs MNKD Comparison
JBLU vs MNKD Comparison
Compare JBLU & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- MNKD
- Stock Information
- Founded
- JBLU 1998
- MNKD 1991
- Country
- JBLU United States
- MNKD United States
- Employees
- JBLU N/A
- MNKD N/A
- Industry
- JBLU Air Freight/Delivery Services
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- JBLU Consumer Discretionary
- MNKD Health Care
- Exchange
- JBLU Nasdaq
- MNKD Nasdaq
- Market Cap
- JBLU 2.1B
- MNKD 1.8B
- IPO Year
- JBLU N/A
- MNKD 2004
- Fundamental
- Price
- JBLU $6.09
- MNKD $6.85
- Analyst Decision
- JBLU Hold
- MNKD Strong Buy
- Analyst Count
- JBLU 10
- MNKD 5
- Target Price
- JBLU $6.43
- MNKD $8.40
- AVG Volume (30 Days)
- JBLU 20.9M
- MNKD 3.2M
- Earning Date
- JBLU 10-29-2024
- MNKD 11-07-2024
- Dividend Yield
- JBLU N/A
- MNKD N/A
- EPS Growth
- JBLU N/A
- MNKD N/A
- EPS
- JBLU N/A
- MNKD 0.08
- Revenue
- JBLU $9,327,000,000.00
- MNKD $267,200,000.00
- Revenue This Year
- JBLU N/A
- MNKD $46.83
- Revenue Next Year
- JBLU $5.55
- MNKD $14.40
- P/E Ratio
- JBLU N/A
- MNKD $86.27
- Revenue Growth
- JBLU N/A
- MNKD 51.35
- 52 Week Low
- JBLU $4.10
- MNKD $3.17
- 52 Week High
- JBLU $8.07
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- JBLU 44.81
- MNKD 49.71
- Support Level
- JBLU $5.82
- MNKD $6.74
- Resistance Level
- JBLU $6.25
- MNKD $7.04
- Average True Range (ATR)
- JBLU 0.36
- MNKD 0.32
- MACD
- JBLU -0.04
- MNKD -0.06
- Stochastic Oscillator
- JBLU 21.97
- MNKD 24.94
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The operating segments of company are Domestic & Canada, Caribbean & Latin America and Atlantic. Majority of revenue is generated from Domestic & Canada segment.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.